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Inflammatory activation of myeloid cells is accompa-
nied by increased glycolysis, which is required for
the surge in cytokine production. Although in vitro
studies suggest that increased macrophage glucose
metabolism is sufficient for cytokine induction, the
proinflammatory effects of increased myeloid cell
glucose flux in vivo and the impact on atheroscle-
rosis, a major complication of diabetes, are un-
known. We therefore tested the hypothesis that
increased glucose uptake in myeloid cells stimulates
cytokine production and atherosclerosis. Overex-
pression of the glucose transporter GLUT1 in
myeloid cells caused increased glycolysis and flux
through the pentose phosphate pathway but did
not induce cytokines. Moreover, myeloid-cell-
specific overexpression of GLUT1 in LDL receptor-
deficient mice was ineffective in promoting athero-
sclerosis. Thus, increased glucose flux is insufficient
for inflammatory myeloid cell activation and athero-
genesis. If glucose promotes atherosclerosis by
increasing cellular glucose flux, myeloid cells do
not appear to be the key targets.
INTRODUCTION
When a myeloid cell encounters inflammatory cues, such as the
Gram-negative bacterial outer membrane component lipopoly-
saccharide (LPS) and cytokines governing innate and adaptive
immunity, such as interferon-g (IFN-g), it undergoes inflamma-
tory activation often referred to as classical (M1) activation.
This process is associated with increased glucose flux through
glycolysis and the pentose phosphate pathway (Vats et al.,356 Cell Reports 7, 356–365, April 24, 2014 ª2014 The Authors2006; Krawczyk et al., 2010, Haschemi et al., 2012; O’Neill and
Hardie, 2013) and reduced mitochondrial oxidation (Vats et al.,
2006; O’Neill and Hardie, 2013). Increased glycolysis in myeloid
cells is not only a consequence of inflammatory activation but is
of critical importance for the ability of these cells to govern in-
flammatory processes (O’Neill and Hardie, 2013; Tannahill
et al., 2013). The shift to glycolysis is due, at least in part, to up-
regulation of the glucose transporter GLUT1 and enzymes in the
glycolytic pathway, including the 6-phosphofructose-2-kinase
isoform PFKFB3, and downregulation of tricarboxylic acid
(TCA)-cycle enzymes (Tannahill et al., 2013), and to increased
production of nitric oxide, which inhibits oxidative phosphoryla-
tion (Everts et al., 2012). Furthermore, the enzyme carbohydrate
kinase-like protein CARKL, which is dramatically downregulated
by LPS in macrophages and regulates flux through the nonoxi-
dative arm of the pentose phosphate pathway, has recently
been shown to inhibit the classical activation of these cells
(Haschemi et al., 2012). Together, these findings indicate that
increased flux of glucose through glycolysis and the pentose
phosphate pathway relative to mitochondrial oxidation is a key
feature of inflammatory myeloid cells required for optimal inflam-
matory functions of these cells.
Increased glucose flux in myeloid cells might explain the
increased inflammatory activity of these cells in diabetes and,
by inference, might also explain complications of diabetes asso-
ciated with increased myeloid cell activation. This is logical
because diabetes is characterized by hyperglycemia and
increased inflammatory activation of myeloid cells (Kanter
et al., 2012; Nagareddy et al., 2013) as well as myelopoiesis
(Nagareddy et al., 2013). A glucose-dependent increase in
production of cytokines by macrophages in the artery wall in
diabetic mice is associated with worsened atherosclerosis (Na-
gareddy et al., 2013), a major complication of diabetes leading
to myocardial infarction and stroke (Bornfeldt and Tabas,
2011). Blocking diabetes-induced inflammatory activation of
myeloid cells prevents diabetes-accelerated atherosclerosis
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(Kanter et al., 2012). Furthermore, inhibition of glycolysis reduces
monocyte adherence to the endothelium, a key event in initiation
of lesions of atherosclerosis (Tsuruda et al., 2012). Finally, down-
regulation of GLUT1 has recently been shown to prevent prolifer-
ation of myeloid cell progenitors (Gautier et al., 2013), which is
associated with worsened atherosclerosis and is stimulated by
hyperglycemia in diabetic mice (Nagareddy et al., 2013). These
findings have led to the hypothesis that hyperglycemia, in part
through increased glucose flux in myeloid cells, contributes to
diabetic vascular disease. This concept is in line with some clin-
ical studies, whereas others have failed to show reduced cardio-
vascular disease following stricter blood glucose control (Brown
et al., 2010). In fact, there is no evidence that the beneficial
effects of stricter blood glucose control observed in some human
studies are due to direct effects of glucose.
In this study, we tested whether increased glucose flux
through glycolysis and the pentose phosphate pathway is suffi-
cient for inflammatory activation of myeloid cells and atheroscle-
rosis, by overexpressing GLUT1—a glucose transporter that is
maximally active at physiological glucose concentrations (Man-
olescu et al., 2007)—under control of the myeloid-selective
CD68 promoter. Our results indicate that increased glucose
flux inmyeloid cells is insufficient to induce an inflammatory state
in these cells and to promote atherosclerosis.
RESULTS AND DISCUSSION
LPS-stimulated bone marrow-derived macrophages (BMDMs)
from low-density lipoprotein (LDL) receptor-deficient (Ldlr/)
mice exhibited increased mRNA levels of hexokinase (Hk1,
Hk2, and Hk3), the first enzyme in glycolysis that converts
glucose to glucose-6-phosphate through an irreversible reaction
(Figures 1A and S1A–S1C). LPS also resulted in increased
GLUT1 (Slc2a1) mRNA levels (Figure 1G). Glycolytic flux is
controlled by 6-phosphofructo-1-kinase, with fructose 2,6-bi-
sphosphate being its most powerful allosteric activator. The
enzyme 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
3 (Pfkfb3) synthesizes fructose 2,6-bisphospate from fructose
6-phosphate and acts as a strong promoter of glycolysis (Ruiz-
Garcı´a et al., 2011). Accordingly, Pfkfb3 mRNA levels were
dramatically upregulated in LPS-stimulated BMDMs (Figure 1B).
The effects of LPS on Hk3 and Pfkfb3 were slightly exacer-
bated in BMDMsdifferentiated in the presence of 25mMglucose
as compared to those differentiated in normal 5.6 mM glu-
cose. The phosphofructose kinase genes Pfkp and Pfkl were
modestly upregulated by LPS, but enzymes downstream of
these initial glycolytic steps were not increased (Figures S1D–Figure 1. LPS-Stimulated Glycolysis and Inflammatory Activation Are D
BMDMs from Ldlr/ mice were used to measure gene expression of enzymes i
(A, B, and D–F) BMDMs differentiated in the presence of 5.6 or 25mMglucose for 7
and subjected to real-time PCR.
(C) Cells were stimulated with LPS (time, 0), the medium was replaced after 1
measurements (using the medium collected between 12 and 24 hr after LPS stim
(G–P) GLUT1 expression was knocked down by siRNA in BMDMs maintained in
whereas glucose consumption, lactate, and IL-6 secretion were measured 18 hr
Results are presented as mean ± SEM (n = 3–5). Statistical analysis was performe
0.01; ***p < 0.001 compared to indicated group. See also Figure S1.
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confirmed that LPS stimulates glycolysis (Figure 1C) both in
normal glucose concentrations and the high glucose concentra-
tions seen in diabetic mice with accelerated atherosclerosis
(Renard et al., 2004). Carkl, which inhibits M1 activation of mac-
rophages and acts to regulate flux through the nonoxidative
branch of the pentose phosphate pathway, wasmarkedly down-
regulated by LPS in both normal and high-glucose conditions
(Figure S1H), consistent with the studies by Haschemi et al.
(2012).
As expected, LPS increased expression of inflammatorymedi-
ators, such as acyl-coenzyme A (CoA) synthetase 1 (Acsl1) and
the cytokines tumor necrosis factor a (Tnfa) and interleukin-6
(Il6) (Figures 1D–1F). ACSL1 promotes an inflammatory pheno-
type of monocytes and macrophages, especially in the setting
of diabetes, and myeloid ACSL1 is required for diabetes-accel-
erated atherosclerosis (Kanter et al., 2012). There was a modest
stimulatory effect of high glucose on Acsl1 and Il6mRNA in LPS-
stimulated macrophages. Thus, LPS-mediated activation of
macrophages results in increased expression of key enzymes
in glycolysis and inflammatory mediators, consistent with pub-
lished studies by Vats et al. (2006), O’Neill and Hardie (2013),
and Tannahill et al. (2013). There was no consistent synergistic
effect of high extracellular glucose. Similar results were obtained
in BMDMs differentiated in the presence of mouse recombinant
macrophage colony-stimulating factor (M-CSF), in which the
effect of high glucose was only observed for Pfkfb3 (Figures
S1I–S1M).
Increased glycolysis is required for the inflammatory activation
of myeloid cells (O’Neill and Hardie, 2013; Tannahill et al., 2013),
but the role of endogenous GLUT1 is unknown. We therefore
knocked down endogenous GLUT1 in BMDMs by small inter-
fering RNA (siRNA). The Slc2a1 siRNA effectively reduced
Slc2a1 mRNA levels, glucose consumption, and release of
lactate in LPS-stimulated BMDMs (Figures 1G–1I), showing
that endogenous GLUT1 is required for LPS-induced glycolysis.
Furthermore, Hk3 was increased by Slc2a1 siRNA in LPS-stimu-
lated BMDMs, whereas Pfkfb3 mRNA and mRNA levels of
inflammatory mediators were reduced in GLUT1-deficient LPS-
stimulated BMDMs, as compared to LPS-stimulated siRNA
control-treated BMDMs (Figures 1J–1O). Consistently, IL-6
secretion was reduced by GLUT1 deficiency (Figure 1P).
Together, our results demonstrate that LPS stimulates glycolysis
and that endogenous GLUT1 is required for both the increased
glycolysis and the inflammatory effects of LPS.
In order to ask whether GLUT1 and increased glucose flux are
sufficient to induce an inflammatory macrophage phenotype,ependent on Endogenous GLUT1 in Macrophages
nvolved in glycolysis and inflammation.
days were stimulated with LPS (5 ng/ml) or vehicle for 6 hr. RNAwas extracted
2 hr with fresh medium, and at 24 hr, the medium was collected for lactate
ulation).
5.6 mM glucose. Changes in mRNA were measured 6 hr after LPS stimulation,
after stimulation. Veh., vehicle.
d by one-way ANOVA followed by Neuman Keuls post hoc test. *p < 0.05; **p <
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murine GLUT1 was stably overexpressed in the J774 macro-
phage cell line and in primary mouse BMDMs. GLUT1 has a
Michaelis-Menten constant (KM) for glucose of 3–7 mM and is
therefore maximally active at physiological glucose levels (Man-
olescu et al., 2007). Because intracellular glucose is rapidly con-
verted into early glycolytic intermediates, intracellular glucose
concentrations are much lower (Cline et al., 1998) than that of
the extracellular environment, and an increase in the number of
GLUT1 molecules on the cell surface necessitates increased
glucose uptake.
J774 macrophages transduced with the GLUT1 retrovirus ex-
hibited an50-fold increase in Slc2a1 (Figure 2A) and increased
[3H]2-deoxyglucose (DOG) uptake (Figure 2B), as comparedwith
cells transduced with the empty pBM-IRES-PURO (pBM) vector.
The overexpressed GLUT1 is therefore functionally active.
Increased glucose flux through glycolysis in GLUT1-overex-
pressing macrophages was reflected by an increased glucose
consumption and lactate release (Figures 2C and 2D), which
were similar to those of LPS-stimulated cells (Figures 2E and
2F). Thus, overexpression of GLUT1 mimics the increased
glucose flux in LPS-stimulated macrophages.
Further analyses of metabolic changes in GLUT1-overex-
pressing J774 macrophages demonstrated a compensatory
reduction in fatty acid b-oxidation (Figures 2G and 2H), but no
significant change in overall oxygen consumption (Figure 2I).
Liquid chromatography/electrospray ionization (LC/ESI) tandem
mass spectrometric analyses revealed a large increase in
the early glycolytic intermediates glucose-6-phosphate and/or
fructose-6-phosphate and a small increase in phosphoenolpyr-
uvate (PEP) in GLUT1-overexpressing cells (Figure 2J). GLUT1-
overexpressing macrophages showed no increase in glucose
flux through the TCA cycle but an increase in flux through the
pentose phosphate pathway (Figure 2L), again consistent with
the effects of LPS in macrophages (Haschemi et al., 2012).
Accordingly, only minor differences were observed in TCA-cycle
intermediates, with a reduction in fumarate and oxaloacetate in
GLUT1-overexpressing cells and a small increase in succinate
(Figure 2K), the latter mimicking LPS-stimulated macrophages
(Tannahill et al., 2013). Acylcarnitines were consistently reduced
in GLUT1-overexpressing cells, indicative of reduced mitochon-
drial activity, whereas unsaturated acyl-CoAs were increased,
probably due to reduced fatty acid oxidation (Figures S2A and
S2B). GLUT1 overexpression was not deleterious to the cells:Figure 2. Overexpression of GLUT1 in Macrophages Mimics the Effect
GLUT1 was overexpressed in J774 macrophages and BMDMs.
(A) Slc2a1 levels were measured by real-time PCR in J774 cells transduced with
(B) Glucose uptake was measured as [3H]2-DOG uptake.
(C–H) Glucose consumption (C and E) and extracellular lactate (D and F) were me
soluble metabolite (ASM) production (H) from [14C]palmitate as measures of b-ox
(I) Oxygen consumption was measured in real time under different glucose cond
(J and K) Glycolytic (J) and TCA-cycle (K) intermediates were measured in J774
(L) CO2 production from glucose utilized through the TCA cycle and the pentose
(M–P) BMDMs were transduced with the CD68-EGFP vector, the CD68-empty ve
microscopy and fluorescence microscopy (M). BMDMs were transduced with CD
and Il6 mRNA (O and P, respectively) were measured by real-time PCR following
Results are presented as mean ± SEM (n = 3–9). Statistical analysis was perform
ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001; ###p < 0.001 compared to indicated
Figure S2.
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lum (ER) stress markers, proliferation, or caspase-3 activity, a
marker of apoptosis, were observed (Figures S2C–S2G).
Next, the inflammatory phenotype of GLUT1-overexpressing
J774 macrophages and BMDMs was evaluated. GLUT1 was
overexpressed using the CD68-GLUT1 vector in BMDMs, which
resulted in a high transduction efficiency, as measured by
expression of EGFP in macrophages transduced with CD68-
EGFP (Figure 2M) and a large increase in Slc2a1 (Figure 2N).
Increased glucose uptake (approximately 80-fold) was observed
in BMDMs transduced with CD68-GLUT1 as compared to those
transducedwith the CD68-EGFP vector, similar to the J774mac-
rophages (Figure 2B). LPS induced Acsl1 and Il6 (Figures 2O and
2P), but GLUT1 overexpression did not affect levels of these
mRNAs. Similar results were obtained in J774 macrophages
overexpressing GLUT1 (Figures S2H–S2L). Thus, although
GLUT1 overexpression mimics the effects of LPS on glucose
flux through glycolysis and the pentose phosphate pathway, it
does not mimic the inflammatory effects of LPS in J774 macro-
phages and mouse BMDMs. These results differ from a recently
published study on the RAW264.7macrophage cell line, in which
overexpression of GLUT1 resulted in increased inflammatory
activation in vitro (Freemerman et al., 2014). Different cell lines
therefore appear to respond differently to GLUT1 overexpres-
sion, whichmakes studies on primarymacrophages andmyeloid
cells in vivo especially important.
The effect of myeloid cell-specific overexpression of GLUT1
in vivo was evaluated next in Ldlr/mice, as shown in Figure 3A.
Bone marrow transplants from congenic CD45.1 mice showed
that the chimerism was high (>90%) in both the primary and
secondary transplanted mice and that myeloid cell GLUT1
expression did not affect chimerism (Figures S3A and S3B).
The CD68 vector resulted in expression of its target gene in
circulating monocytes and neutrophils as well as in macro-
phages (79.2% ± 4.1% of BMDMs isolated from mice carrying
EGFP under control of the CD68 vector were EGFP positive),
but not in B and T cells (Figures S3C and S3D).
In order to verify that macrophage glucose uptake is increased
by CD68-GLUT1 expression in vivo, 18F-flurodeoxyglucose
(18FDG) positron emission tomography (PET) was used. Perito-
neal macrophages were elicited by thioglycollate in mice with
CD68-empty and CD68-GLUT1 bone marrow, and 18FDG up-
take was measured in the peritoneal cavity 5 days later. Foci inof LPS on Glycolysis, but Not Inflammation
empty pBM or a vector encoding GLUT1.
asured by colorimetric kits in the same samples. CO2 production (G) and acid-
idation are shown.
itions.
macrophages by LC/ESI-tandem mass spectrometry (MS/MS).
phosphate pathway (PPP).
ctor, or the CD68-GLUT1 vector. The cells were visualized by phase-contrast
68-GLUT1 or empty control vector, and levels of Slc2a1 mRNA (N) and Acsl1
16 hr stimulation with and without LPS in the presence of 5.6 mM glucose.
ed by one-way ANOVA followed by Neuman Keuls post hoc test or two-way
group or control. Isoc, isocitrate; Succ, succinate; Fum, fumarate. See also
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the peritoneal cavity in CD68-GLUT1 mice showed significantly
elevated 18FDG uptake, as compared to CD68-empty mice.
The number of peritoneal macrophages was similar (Figures
3B–3E). These results demonstrate that CD68-GLUT1 results
in increased glucose uptake in macrophages in vivo.
At the end of the 22-week study, Slc2a1mRNA levels in circu-
lating myeloid cells were elevated by 30-fold, whereas Tnfa was
not increased (Figures 3F and 3G). Myeloid GLUT1 overexpres-
sion also had no effect on hematopoiesis (Figure 3H). Further-
more, myeloid-targeted expression of GLUT1 did not affect
blood cholesterol or glucose levels, glucose tolerance, or plasma
levels of lactate, triglycerides, or IL-6 (Figures S3E–S3J). Perito-
neal macrophages from the samemice exhibited large increases
in glucose uptake and Slc2a1 mRNA (Figures 3I and 3J), but no
increase in TNF-a or IL-6 (Figures 3K–3N). Thus, increased
glucose flux due to GLUT1 overexpression is insufficient to pro-
mote an inflammatory myeloid cell phenotype.
Consistent with the lack of effect of GLUT1 on inflammatory
mediators, no effect of myeloid GLUT1 overexpression was
observed on atherosclerotic lesion size in the aortic sinus, aorta,
or brachiocephalic artery (BCA). Lesion neutral lipid content,
measured as oil red O staining, and macrophage accumulation,
measured as Mac-2-positive lesion area, also were no different
between the groups (Figures 4A–4C, 4H, 4I, and 4K–4N). Lesion
severity was greatest in the aortic sinus, where the lesions
contained necrotic cores, fibrous areas, and cholesterol clefts
(Figures S4A–S4C). Aortic lesions, especially in the lesser curva-
ture of the arch, were of an intermediate maturity, containing
fibrous caps (Figures 4A and 4B). The BCA lesions were early
fatty streaks, consisting primarily of macrophages (Figure 4C).
Myeloid cell GLUT1 expression had no effect on lesion severity
in any of these sites, including necrotic cores and intraplaque
hemorrhage (Figures 4J and S4D). Lesion macrophages from
mice with GLUT1-overexpressing myeloid cells exhibited
intense GLUT1 immunoreactivity, whereas lesion macrophages
from control mice had weak GLUT1 immunoreactivity (Figures
4D–4G).
Together, our studies show that increased glucose flux selec-
tively in myeloid cells is insufficient for increased inflammatory
activity and atherosclerosis. These studies may be of high rele-
vance for our understanding of atherosclerosis associated with
diabetes and other inflammatory states. Several hyperglycemic
mouse models exhibit accelerated atherosclerosis (Bornfeldt
and Tabas, 2011) due to increased macrophage accumulationFigure 3. Overexpression of GLUT1 in Myeloid Cells In Vivo Does Not
(A) Study design. 5-FU, fluorouracil.
(B–E) 18FDG PET analysis of peritoneal macrophages in Ldlr/ mice fed the low
arrows, and examples of the analyzed areas are shown in higher magnification
peritoneal macrophages were fixed. The next day, the number of cells was dete
(F and G) Slc2a1 and Tnfa mRNA levels were measured by real-time PCR in leuk
(H) Circulating leukocyte populations (percentage [%] of total live cells) were anal
expressed as percentage (%) of total monocytes. Neutros, neutrophils. White ba
(I–N) At the end of the 22-week study, thioglycollate-elicited macrophages were
(I) Glucose uptake was measured by [3H]2-DOG uptake.
(J–L) Slc2a1 (J), Tnfa (K), and Il6 (L) mRNA levels were measured by real-time PC
(M and N) Macrophages were stimulated in the presence or absence of LPS for
Results are presented as mean ± SEM (n = 3–5). Statistical analysis was perfor
Neuman Keuls post hoc test. *p < 0.05; **p < 0.01; ***p < 0.001 compared to em
362 Cell Reports 7, 356–365, April 24, 2014 ª2014 The Authorsin the vessel wall (Renard et al., 2004). The role of increased
glucose exposure of myeloid cells has been addressed in
in vitro studies, many of which demonstrate that elevated
glucose levels enhance production of cytokines (reviewed in
Nishizawa and Bornfeldt, 2012; Bornfeldt and Tabas, 2011). It
has therefore long been hypothesized that increased glucose
levels promote cytokine release from macrophages in vivo
and, as a consequence, promote atherosclerosis. The present
study clearly demonstrates that increased glucose flux in
myeloid cells is insufficient to promote atherosclerosis, at least
under the conditions used in this study. Although GLUT1 overex-
pression had no effect on lesions of different severity at three
different sites, it is possible that other conditions, such as a
high-fat diet, might have revealed an effect. In addition, glucose
might have important effects on other vascular cells, on other
populations of bone marrow-derived cells, or extracellular
glucose could exert proatherosclerotic effects, for example
through formation of advanced glycation end products, because
glucose lowering in diabetic mice prevents the detrimental ef-
fects of diabetes on atherosclerosis regression (Nagareddy
et al., 2013), and GLUT1 overexpression in smooth muscle cells
results in increased recruitment of neutrophils to sites of vascular
injury (Adhikari et al., 2011).
One caveat is that our studies are based on mouse models. In
patients with diabetes, multiple other metabolic arrangements
independent of or indirectly related to glucose levels could
contribute to an increased inflammatory myeloid cell phenotype
and atherosclerosis. Indeed, in preliminary studies, we noted
that ACSL1 (a marker of inflammatory activation) gene expres-
sion was modestly increased in CD14+ monocytes from
patients with type 1 diabetes as compared to matched controls
(p < 0.05; n = 14), consistent with previous studies (Kanter et al.,
2012). There was no correlation between ACSL1 mRNA and the
glycolytic mediators PFKFB3 and SLC2A1 in these cells (p >
0.10). Thus, there appears to be a disconnect between dia-
betes-induced myeloid cell inflammation and glycolysis in
human and mouse myeloid cells. Further studies are needed
to identify the mechanism of diabetes-induced activation of
myeloid cells.
In summary, these studies demonstrate the role of increased
glucose flux in a specific cell type with a key role in atheroscle-
rosis and set the stage for future studies to systematically inves-
tigate the role of glucose flux in cell types involved in this disease.
Our findings suggest that increased glycolysis is required, but isIncrease Their Inflammatory Phenotype
-fat semipurified diet. Foci of peritoneal macrophages are indicated by white
under the whole-mouse images. At the end of the 30 min image collection,
rmined by counting (C).
ocytes 22 weeks after bone marrow transplants.
yzed by flow cytometry. Ly6Chi and Ly6Clo monocyte (Monos) populations are
rs, CD68-empty; gray bars, CD68-GLUT1.
collected and adherence purified for 1 hr.
R.
24 hr, and TNF-a (M) and IL-6 (N) secretion was measured by ELISA.
med by two-tailed unpaired Student’s t test or one-way ANOVA followed by
pty control virus. See also Figure S3.
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not sufficient, for inflammatory activation of myeloid cells and
atherosclerosis. These findings have important implications for
studies on diabetic vascular disease; a multifactorial disease in
which the role of glucose is still uncertain.
EXPERIMENTAL PROCEDURES
All animal studies were approved by the Institutional Animal Care and Use
Committee at the University of Washington.
Generation of Retroviral Vectors for Overexpression of GLUT1
Targeted to Myeloid Cells
Murine GLUT1 cDNA was cloned into the pBM vector or the pLZRS-SIN-
CD68S (CD68) vector, as previously described (Gough and Raines, 2003).
Phoenix ecotropic cells were used to generate retrovirus. The pLZRS-SIN-
CD68S vector was used to overexpress GLUT1 or EGFP specifically inmyeloid
cells in vivo, following transduction of bone marrow stem cells.
Atherosclerosis Studies
Myeloid cell-selective overexpression of GLUT1 or EGFP in Ldlr/ mice was
achieved by transducing bone marrow stem cells with the CD68-GLUT1,
CD68-EGFP, or CD68-empty control retroviral vectors. Briefly, the transduced
cells were injected into irradiated 8- to 10 week-old male C57BL/6 mice. The
mice were allowed to recover for 7 weeks to reconstitute bone marrow.
Bone marrow cells were then harvested and transplanted to irradiated 8- to
10-week-old female Ldlr/mice (Jackson Laboratory). After a 7-week recov-
ery period, the Ldlr/mice were fed a low-fat semipurified diet described pre-
viously (Kanter et al., 2012) for 22 weeks. At the end of the study, blood was
collected, andmice were perfusion fixed under physiological pressure (Renard
et al., 2004). A subset of mice was injected intraperitoneally with thioglycollate
for isolation of peritoneal macrophages (Kanter et al., 2012). Atherosclerotic
lesions in the aorta, BCA, and aortic sinus were evaluated. The sinus was
cryosectioned, and oil red O staining was used to evaluate lesion neutral lipid
accumulation. The same sections were then used for Movat’s pentachrome
stain. The BCA was paraffin embedded and serial sectioned (Kanter et al.,
2012), and adjacent sections were used for Movat’s pentachrome stain and
immunohistochemistry for Mac-2 or GLUT1. Aortas were sectioned longitudi-
nally and were used for lesion analysis and Mac-2 immunohistochemistry. All
measurements were done in a masked fashion. Supplemental Experimental
Procedures can be found in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.03.028.
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